Cargando…

Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia

Detalles Bibliográficos
Autores principales:	Nilsson, Malin S., Hallner, Alexander, Brune, Mats, Nilsson, Staffan, Thorén, Fredrik B., Martner, Anna, Hellstrand, Kristoffer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027927/ https://www.ncbi.nlm.nih.gov/pubmed/31853942 http://dx.doi.org/10.1111/bjh.16320

Ejemplares similares

Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
por: Nilsson, Malin S., et al.
Publicado: (2019)

Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia
por: Hussein, Brwa Ali, et al.
Publicado: (2021)

Corrigendum: Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia
por: Hussein, Brwa Ali, et al.
Publicado: (2022)

NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance
por: Martner, Anna, et al.
Publicado: (2015)

Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
por: Sander, Frida Ewald, et al.
Publicado: (2017)

Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2021)

Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia
por: Martner, Anna, et al.
Publicado: (2015)

HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia
por: Komic, Hana, et al.
Publicado: (2023)

Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia
por: Sander, Frida Ewald, et al.
Publicado: (2016)

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia
por: Bernson, E, et al.
Publicado: (2017)

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells
por: Hussein, Brwa Ali, et al.
Publicado: (2023)

Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells
por: Werlenius, Olle, et al.
Publicado: (2016)

Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2
por: Kiffin, Roberta, et al.
Publicado: (2018)

Induction and subsequent decline of S1-specific T cell reactivity after COVID-19 vaccination
por: Törnell, Andreas, et al.
Publicado: (2023)

Low Incidence of Reinfection With Endemic Coronaviruses Diagnosed by Real-Time PCR
por: Ringlander, Johan, et al.
Publicado: (2020)

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2018)

NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease
por: Aydin, Ebru, et al.
Publicado: (2018)

Immunotherapy using BCG during remission induction and as the sole form of maintenance in acute myeloid leukaemia.
por: Summerfield, G. P., et al.
Publicado: (1979)

IFNL4 Genotypes Predict Clearance of RNA Viruses in Rwandan Children With Upper Respiratory Tract Infections
por: Rugwizangoga, Belson, et al.
Publicado: (2019)

Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2–Specific T Cells in Whole Blood
por: Törnell, Andreas, et al.
Publicado: (2022)

Role of the ERK Pathway for Oxidant-Induced Parthanatos in Human Lymphocytes
por: Akhiani, Ali A., et al.
Publicado: (2014)

Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity
por: Einarsdottir, Sigrun, et al.
Publicado: (2022)

Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
por: Harris, R., et al.
Publicado: (1978)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
por: Maravalle, Denise, et al.
Publicado: (2022)

Transient and durable T cell reactivity after COVID-19
por: Martner, Anna, et al.
Publicado: (2022)

Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis
por: Johansson, Junko, et al.
Publicado: (2019)

NOX2 in autoimmunity, tumor growth and metastasis
por: Martner, Anna, et al.
Publicado: (2018)

Prospects for achieving treatment‐free remission in chronic myeloid leukaemia
por: Saglio, Giuseppe, et al.
Publicado: (2020)

Persistence of UBTF tandem duplications in remission in acute myeloid leukaemia
por: Harrop, Sean, et al.
Publicado: (2023)

Acute myeloid leukaemia relapse presenting as cardiac myeloid sarcoma
por: Waselewski, Alexander, et al.
Publicado: (2018)

Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation
por: Einarsdottir, Sigrun, et al.
Publicado: (2022)

Proceedings: Active immunotherapy in acute myeloid leukaemia.
por: Freeman, C. B., et al.
Publicado: (1975)

Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia
por: Khan, Ghazala Naz, et al.
Publicado: (2019)

Isolated CNS leukaemic relapse in acute myeloid leukaemia
por: Essa, Amr, et al.
Publicado: (2019)

NOX2-Derived Reactive Oxygen Species in Cancer
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2020)

Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells
por: Wenger, Anna, et al.
Publicado: (2017)

Immunotherapy in leukaemia: Immunotherapy in leukaemia
por: Mu, Xingmei, et al.
Publicado: (2023)

Immunotherapy of acute myeloid leukaemia. Medical Research Council.
Publicado: (1978)

Increase in "Null" cells in acute lymphocytic leukaemia in remission on long-term immunotherapy.
por: Joseph, R. R., et al.
Publicado: (1976)

Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023
por: Egan, Grace, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3kish6vbphshqifnes5hqbd0bh